Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of volasertib combined with afatinib, in advanced solid tumors.
Machiels JP, Peeters M, Herremans C, Surmont V, Specenier P, De Smet M, Pilz K, Strelkowa N, Liu D, Rottey S. Machiels JP, et al. Among authors: rottey s. Cancer Chemother Pharmacol. 2015 Oct;76(4):843-51. doi: 10.1007/s00280-015-2860-2. Epub 2015 Sep 8. Cancer Chemother Pharmacol. 2015. PMID: 26349473 Clinical Trial.
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels JP. Vermorken JB, et al. Among authors: rottey s. Ann Oncol. 2013 May;24(5):1392-400. doi: 10.1093/annonc/mds633. Epub 2013 Jan 4. Ann Oncol. 2013. PMID: 23293114 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E. Maison-Blanche P, et al. Among authors: rottey s. J Cardiovasc Pharmacol. 2013 Jun;61(6):495-504. doi: 10.1097/FJC.0b013e31828b73ff. J Cardiovasc Pharmacol. 2013. PMID: 23429593 Clinical Trial.
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengeløv L, Van Veldhuizen P, Agarwala SS, Sémiond D, Chadjaa M, Shen L, Wade JL. Maison-Blanche P, et al. Among authors: rottey s. Cancer Chemother Pharmacol. 2014 Jun;73(6):1241-52. doi: 10.1007/s00280-014-2460-6. Epub 2014 Apr 10. Cancer Chemother Pharmacol. 2014. PMID: 24718982 Clinical Trial.
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Machiels JP, et al. Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16. Lancet Oncol. 2015. PMID: 25892145 Clinical Trial.
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP. Seront E, et al. Among authors: rottey s. BJU Int. 2016 Sep;118(3):408-15. doi: 10.1111/bju.13415. Epub 2016 Feb 11. BJU Int. 2016. PMID: 26779597 Clinical Trial.
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N. Van Praet C, et al. Among authors: rottey s. Urol Oncol. 2016 Jun;34(6):254.e7-254.e13. doi: 10.1016/j.urolonc.2015.12.017. Epub 2016 Feb 2. Urol Oncol. 2016. PMID: 26850781
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
Azaro A, Rodón J, Machiels JP, Rottey S, Damian S, Baird R, Garcia-Corbacho J, Mathijssen RHJ, Clot PF, Wack C, Shen L, de Jonge MJA. Azaro A, et al. Among authors: rottey s. Cancer Chemother Pharmacol. 2016 Dec;78(6):1185-1197. doi: 10.1007/s00280-016-3175-7. Epub 2016 Oct 27. Cancer Chemother Pharmacol. 2016. PMID: 27796539 Free PMC article. Clinical Trial.
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D, Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S. Machiels JP, et al. Among authors: rottey s. Oncologist. 2016 Dec;21(12):1416-e17. doi: 10.1634/theoncologist.2016-0296. Epub 2016 Nov 30. Oncologist. 2016. PMID: 27903924 Free PMC article. Clinical Trial.
186 results